Business
Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting
BOULDER, Colo., May 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) announced that that it will present data from the Phase 3 COLUMBUS Trial of
About this update from Array Technologies, Inc.
[{"type":"text","content":"BOULDER, Colo., May 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) announced that that it will present data from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant melanoma in an oral poster discussion on June 3, 2019, at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. Landmark overall survival (OS) and progression-free survival (PFS), as well as subgroup analyses and updated safety and tolerability, will be presented. \n\"We are pleased to report a 4-year landmark analysis of the long-term benefit of BRAFTOVI + MEKTOVI from the COLUMBUS trial,\" said Ron Squarer, Chief Executive Officer. \"Both the overall survival and progression-free survival data remain consistent with prior reports and continue to represent new benchmarks for BRAF + MEK inhibitor combinations in the treatment of BRAFV600-mutant advanced melanoma. We remain steadfastly committed to developing products that treat cancers in dire need of effective therapies.\"\nAcross arms, median follow-up for OS was 48.6 months, with a median OS of 33.6 months (95% CI, 24.4–39.2) for BRAFTOVI, 450 mg daily + MEKTOVI, 45 mg twice daily, compared to 16.9 months (95% CI, 14.0–24.5) for vemurafenib, consistent with prior readouts. Compared to vemurafenib, BRAFTOVI, 450 mg daily + MEKTOVI, 45 mg twice daily, decreased the risk of death by 39% (HR, 0.61 [95% CI, 0.48–0.79]). \nUpdated median progression-free survival (PFS) also remained consistent and was 14.9 months (95% CI, 11.0–20.2) with BRAFTOVI, 450 mg daily + MEKTOVI, 45 mg twice daily, compared to 7.3 months (95% CI, 5.6–8.2) with vemurafenib (HR, 0.52 [95% CI, 0.40–0.67]). \nPoster Discussion\nThe abstracts can be accessed through the ASCO website, http://abstract.asco.org/. Following the poster presentation on Monday, June 3, 2019, the poster will be available as a PDF on Array's website at www.arraybiopharma.com.\nAbout BRAF-mutant Metastatic MelanomaMelanoma develops when unrepaired DNA damage to skin cells triggers mutations that may lead them to multiply and form malignant tumors. Metastatic melanoma is the most serious and life-threatening type of skin cancer and is associated with low survival rates. [1,2] There are a variety of gene mutations that can lead to metastatic melanoma. The most common genetic mutation in metastatic mel...